

B1

--10. A method for the treatment of ~~pre-existing~~ glomerulonephritis in a patient in need of such treatment comprising introducing an ~~antibody~~ specific to complement component C5 into the patient's bloodstream in an amount effective to substantially reduce the cell-lysing ability of complement present in the patient's blood.

REMARKS

I. Introduction

This is in response to the Office Action dated May 22, 1996. A petition under 37 CFR §1.136 and the required fee requesting a two month extension in which to file this amendment is being filed herewith. With the extension, this response was due on October 22, 1996. No additional fees are believed to be necessary for the filing of this amendment, but if such fees are required, applicants request that this be considered a petition therefor, and the Commissioner is hereby authorized to charge any additional fees which may be required for the filing of this amendment to Deposit Account No. 01-0483.

Applicants note with appreciation the Examiner's withdrawal of the previous rejections under 35 U.S.C. §112, first and second paragraphs.

II. The §103 Rejections

In the May 22 Office Action, the Examiner rejected applicant's pending claims 1-5 under 35 U.S.C. § 103 as